Imugene (ASX: IMU) steps up dosage at groundbreaking VAXINIA cancer trial (w/ Leslie Chong)

Small Caps

内容由Small Caps提供。所有播客内容（包括剧集、图形和播客描述）均由 Small Caps 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

4M ago 19:18

MP3•单集首页

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

See omnystudio.com/listener for privacy information.

125集单集

#Business News #News #Small Caps #Trading #Business